Genta Inc. (GNTA.OB) To Be Granted Two Key European Patents for Genasense®
Genta Incorporated announced that the European Patent Office intends to grant two key patents related to the company’s intellectual property position on Genasense® (oblimersen sodium) Injection. These two patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.
Sharps Compliance Corp. (SCOM.OB) Announces Record Revenues
Sharps Compliance Corp. announced record revenues for the first quarter of fiscal 2009. Revenues jumped 26%, to $4.3 million, from the same quarter last year. Sharps also reported record customer billings of $4.7 million for the quarter, a 30% increase over the same period the year before
BioSolar, Inc (BSRC.OB) Files Patent for its Environmentally-Friendly Solar Cell Component
BioSolar, Inc. (BSRC.OB) is pleased to announce that earlier this week it filed a patent application to protect the unique inventions and processes behind its proprietary bio-based backsheet. The extensive patent application is expected to provide BioSolar full protection of its new BioBacksheet™ technology.